-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Iodine I 131 Apamistamab in Refractory Anemia With Ringed Sideroblasts
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iodine I 131 Apamistamab in Refractory Anemia With Ringed Sideroblasts report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Iodine I 131 Apamistamab in...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Iodine I 131 Apamistamab in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iodine I 131 Apamistamab in Refractory Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Iodine I 131 Apamistamab in Refractory...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Iodine I 131 Apamistamab in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iodine I 131 Apamistamab in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Iodine I 131 Apamistamab in Relapsed...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Iodine I 131 Apamistamab in Multiple Myeloma (Kahler Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iodine I 131 Apamistamab in Multiple Myeloma (Kahler Disease) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Iodine I 131 Apamistamab in Multiple...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Iodine I 131 Apamistamab in Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iodine I 131 Apamistamab in Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Iodine I 131 Apamistamab in Chronic...
-
Sector Analysis
IT Management Market Size, Trends, Drivers and Challenges, Vendor Landscape, Opportunities and Forecast to 2027
IT Management Market Overview The IT Management market size was pegged at more than $195 billion in 2022. The market is expected to grow at a CAGR of more than 7% during the forecast period (2022-2027). The speed at which businesses are completing their digital transformation initiatives is encouraging for the IT management sector since this sector is vital in helping businesses create scalable, reliable IT infrastructures that can support their digital endeavors. IT Management Market Outlook, 2022-2027 ($ Billions)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Iodine I 131 Apamistamab in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iodine I 131 Apamistamab in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Iodine I...
-
Company Insights
NewAvis Budget Group (Avis) – Digital Transformation Strategies
Avis Digital Transformation Strategies Overview Avis Budget Group (Avis) has been focusing on using AI and machine learning, big data, cloud, connected car technology, Internet of Things (IoT), electric vehicles, autonomous vehicles, the future of work, and e-commerce to digitally transform its operations. The annual ICT spending of Avis was estimated at $450.2 million for 2023. A major share of this spending is earmarked for acquiring software, network and communications, and hardware from vendors. Avis offers car sharing as well...
-
Company Insights
Duke Energy Corporation – Digital Transformation Strategies
Duke Energy Digital Transformation Strategies Overview Duke Energy has been focusing on using artificial intelligence, cloud-based mobile applications, big data, and augmented reality to digitally transform its operations. The annual ICT spending of Duke Energy was estimated at $923.1 million for 2023. A major share of this spending is earmarked for acquiring software, hardware, and ICT services from vendors. Duke Energy Corporation (Duke Energy) is an integrated energy utility company based in Charlotte, North Carolina (US). It is engaged in...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Actimab-A in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Actimab-A in Refractory Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Actimab-A in Refractory Acute Myeloid Leukemia Drug Details: Actimab-A (HuM195-Ac-225)...